Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

  • Technology appraisal guidance
  • TA195
  • Published: 
Download guidance (PDF)

8 Review of guidance

8.1 The guidance on these technologies will be considered for review by the Guidance Executive in June 2013. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
August 2010